AA
CRSP icon

AlphaMark Advisors’s CRISPR Therapeutics CRSP Stock Holding History

AlphaMark Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-94
Closed -$4K – 488
2019
Q3 		$4K Hold
94
– – ﹤0.01% 407
2019
Q2 		$4K Hold
94
– – ﹤0.01% 431
2019
Q1 		$3K Hold
94
– – ﹤0.01% 437
2018
Q4 		$3K Hold
94
– – ﹤0.01% 414
2018
Q3 		$4K Buy
+94
New +$4.92K ﹤0.01% 435

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AlphaMark Advisors's CRSP Position: Q4 2019 in Review

AlphaMark Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2019, closing a stake of 94 shares — an estimated $4K sold.

AlphaMark Advisors first reported a position in CRSP in Q3 2018 and held it in 5 quarters. The position peaked at $4K in Q3 2019. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • AlphaMark Advisors reported no remaining CRISPR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • AlphaMark Advisors sold 94 CRISPR Therapeutics shares in Q4 2019, an estimated $4K.
  • AlphaMark Advisors first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 5 quarters.
  • AlphaMark Advisors's CRISPR Therapeutics position peaked at $4K in Q3 2019.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.